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Abstract: The Hedgehog (HH) signaling pathway plays an important role in embryonic and 
postnatal vascular development and in maintaining the homeostasis of organs. Under physiological 
conditions, Sonic Hedgehog (SHH), a secreted protein belonging to the HH family, regulates 
endothelial cell growth, promotes cell migration and stimulates the formation of new blood vessels. 
The present review highlights recent advances made in the field of SHH signaling in endothelial 
progenitor cells (EPCs). The canonical and non-canonical SHH signaling pathways in EPCs and 
endothelial cells (ECs) related to homeostasis, SHH signal transmission by extracellular vesicles 
(EVs) or exosomes containing single-strand non-coding miRNAs and impaired SHH signaling in 
cardiovascular diseases are discussed. As a promising therapeutic tool, the possibility of using the 
SHH signaling pathway for the activation of EPCs in patients suffering from cardiovascular diseases 
is further explored. 
Keywords: sonic hedgehog; endothelial cells; endothelial progenitor cells; canonical signaling; non-
canonical signals; extracellular vesicles 
 
1. Introduction 
Endothelial progenitor cells (EPCs) were first isolated from adult peripheral blood (PB) in 1997 
[1]. Circulating EPCs are bone marrow (BM)-derived cells that incorporate into the foci of 
physiological or pathological neovascularization to form new blood vessels [2]. In situ, circulating 
EPCs localize at sites of neovascularization and differentiate into endothelial cells (ECs). This process 
is similar to vasculogenesis, which involves the formation of new blood vessels during embryonic 
development. In adult organisms, a reservoir of EPCs from bone marrow contributes to postnatal 
neovascularization [3]. The discovery of EPCs has expanded the field of vascular biology beyond the 
conventional EC biology and now is applied for studies involving organ regeneration and vascular 
diseases. Several research investigations related to regenerative medicine have aimed at elucidating 
the differentiation cascade of EPCs and their role in the origin of vascular development. Two types 
of EPCs have been described, namely, hematopoietic including circulating EPCs and non-
hematopoietic EPCs. Few non-hematopoietic EPCs include endothelial out-growth cells (EOCs) and 
tissue resident c-kit+/CD45− progenitor cells [2,4,5]. Several signaling cascades are common to 
hematopoietic EPCs, non-hematopoietic EPCs and differentiated ECs. However, distinct signaling 
mechanisms associated with the differentiation and subsequent bioactivity of EPCs reveals their 
unique role in vascular development and pathology during the postnatal period. 
The Hedgehog (HH) signaling pathway coordinates embryonic and postnatal angiogenesis as 
well as organogenesis. In vertebrates, during the early embryonic development, HH morphogens 
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play a crucial role in the development of organs such as limbs [6,7], neurons (axon elongation and 
astrocyte development) [8–10] and cardiac and vascular structures for septal cardiogenesis, 
angiogenesis and vasculogenesis [11–15]. Mammals have three genes with homology to the Hh gene, 
namely, Sonic hedgehog (SHH), Indian hedgehog (IHH) and Desert hedgehog (DHH). The SHH 
signaling pathway has drawn research interest as it induces postnatal vasculogenesis under 
homeostasis and pathological conditions [16–20]. 
The present review focuses on the recent research developments in EPC biology, namely, (i) 
canonical and non-canonical SHH signaling pathways in EPCs and EC, related to homeostasis, (ii) 
SHH signal transmission by extracellular vesicles such as exosomes containing single-strand non-
coding miRNAs and (iii) impaired SHH signaling in cardiovascular diseases. In conclusion, the role 
of activated SHH signaling pathway in EPCs as a promising therapeutic tool for cardiovascular 
patients has been explored. 
1.1. SHH Signaling Pathways in Vascular Development 
Classical canonical SHH signaling is initiated by the binding of SHH morphogens to 12-pass 
transmembrane cell surface receptor Patched 1 (PTCH 1) present on the target cell [21]. De-repressed 
smoothened (SMO) protein, a central signal transducer of the SHH signaling pathway, activates the 
downstream glioma-associated oncogene homolog (GLI) family of transcription factors, namely, 
GLI1, GLI2 and GLI3 (Figure 1). Direct binding of suppressor of fused (SUFU) to GLI transcription 
factors negatively regulates GLI-mediated transcription by inhibiting their nuclear entry and ability 
to transcribe DNA [22]. At the nuclear level, accumulation of GLI transcription factors activate target 
genes associated with proliferation (Cyclin-D1, MYC), apoptosis (BCL-2), angiogenesis (ANG)1/2, 
PDGF-BB, VEGF)), epithelial-to-mesenchymal transition (SNAIL) and stem cell self-renewal 
(NANOG, SOX2) [21,23,24]. 
 
Figure 1. Canonical and Non-Canonical Sonic hedgehog (SHH) signaling pathway in endothelial 
progenitor cells (EPCs) and endothelial cells (ECs). SHH molecule binds and activate the 12-pass 
transmembrane cell surface receptor Patched 1 (PTCH 1) that inhibits the smoothened (SMO) receptor 
to activate the binding of suppressor of fused (SUFU) and glioma-associated oncogene homolog1-A 
(GlLI 1A) to form a complex by autophosphorylation. EPCs are mostly activated by the non-canonical 
SHH signaling pathway in angiogenesis. 
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Recent research in the field of vascular biology reveals significant contribution of the non-
canonical SHH signaling rather than canonical SHH signaling in vascular development under 
homeostasis or pathological conditions [13,17,25]. In endothelial cells, SHH morphogens trigger the 
non-canonical SHH signaling pathway leading to vascular differentiation, maturation and function 
[14,17–19,26,27]. Stimulation of a confluent endothelial monolayer of cells with recombinant SHH 
molecules but not IHH or DHH morphogens, resulted in a change in the overall morphology of cells 
from the typical EC “cobblestone” shape to a swirling pattern of elongated cells oriented in bundles, 
a pattern characteristic of activated ECs engaged in angiogenesis [25,28]. 
In one of the non-canonical SHH signaling pathways, SHH proteins could activate membrane 
RhoA GTPase in a SMO/GI protein-dependent manner [25]. The membrane RhoA family of small 
GTPases play an important role in cell migration and invasion by orchestrating guanine nucleotide 
exchange factors and GTPase-activating protein complexes [29]. Cell migration mediated by RhoA 
GTPase signaling is specific in different cell lines. More than 20 members of the Rho family have been 
discovered and are divided into classical and non-typical types. The RhoA GTPase responsible for 
the activation of the Gi/SMO complex in ECs is less studied [30]. In vitro, the tube formation assay 
showed that Hh proteins stimulated tubulogenesis by inducing rapid activation of RhoA levels in 
human umbilical-vein ECs via SMO and GI proteins, while inhibition of RhoA activation hindered 
tube formation [25,31]. Binding of SHH molecule to RhoA GTPase brought forth a 3-fold increase in 
the concentration of RhoA GTPase, thereby delivering a strong angiogenic signal required to activate 
the non-canonical SMO-dependent SHH signaling pathway for the maturation of EPCs to ECs (Figure 
1) [25,27,31]. 
Survival of ECs is mediated by a decrease in caspase-3 activity that inhibits the PTCH1 pro-
apoptotic function in a SMO-independent manner [25,27]. A combined transcriptomic and proteomic 
approach identified a 101-gene endothelial signature that could be used to characterize endothelial 
commitment. The HH-interacting protein regulates GLI-dependent canonical HH signaling and is a 
strong negative regulator of the late endothelial progenitor cells (LEPCs). Knockdown of hedgehog-
interacting protein in LEPCs improves the angiogenic activity and enhances their survival under 
oxidative stress [32]. Thus, exogenous administration of SHH could be beneficial for the survival of 
EPCs after the onset of ischemic events. 
SHH morphogens activate the Rho-associated protein kinase (Rho/ROCK) pathway and 
enhances the expression of downstream matrix metalloproteinase 9 (MMP-9), osteopontin (OPN) and 
platelet derived growth factor (PDGF-BB) (Figure 1), which are essential for SHH-induced 
angiogenesis in vitro [14,25,27]. An in vivo mouse corneal angiogenesis model was used to investigate 
the potential involvement of SMO, the Rho/ROCK pathway, MMP-9, OPN and the GLI transcription 
factors in SHH-induced angiogenesis. Pellets containing phosphate-buffered saline (PBS) or 
cyclopamine (SMO protein inhibitor) alone and in combination with SHH, were implanted and the 
extent of angiogenesis was evaluated by in vivo fluorescein-BS-1 lectin perfusion. PBS+ SHH 
significantly increased angiogenesis, which was inhibited by cyclopamine. To analyze the role of the 
Rho/ROCK pathway in SHH signaling, pellets containing PBS, SHH, Y27632 (ROCK inhibitor), or 
SHH+Y27632 (ROCK inhibitor) were implanted. Significantly enhanced downstream targets of 
ROCK, MMP-9 and OPN dependent angiogenesis were observed in the SHH treated group 
compared to those in the SHH+Y27632 treated group that showed no significant changes [27]. A 
mouse corneal angiogenesis model demonstrated SHH-dependent PDGF-BB–induced pericyte cell 
recruitment, essential for the maturation of newly formed blood vessels [14]. 
Taken together, the above results prove the vital role of SHH morphogens in activating the non-
canonical rather than the canonical signaling pathway in EPCs and ECs, thereby regulating 
migration, angiogeneic bioactivity, survival and maturation. 
Gupta et al., recently reported a non-canonical SHH signaling pathway with an indirect effect of 
SHH molecules in mediating angiogenesis in EPCs and ECs. They demonstrated that in vitro, the 
effect of SHH on the proliferation and migration of ECs was limited by direct incubation of SHH in 
culture but was significantly enhanced in the presence of conditioned media from SHH-treated 
fibroblasts or stromal cells. In addition, treatment of fibroblasts with SHH significantly enhanced the 
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expression profile of angiogenic growth factors including PDGF-B, VEGF-A, hepatocyte growth 
factor (HGF) and insulin-like growth factor (IGF). Among these, PDGF-B was most predominantly 
upregulated and might have contributed to the formation of large neo-vessels associated with SHH-
induced indirect angiogenesis [26]. In vivo, in a corneal angiogenesis model, administration of 
exogenous SHH showed no significant difference in corneal angiogenesis between endothelial-
specific smoothened knockout (eSmoNull) and eSmoWT mice. An in vivo hind-limb ischemia (HLI) 
model in eSmoNull and eSmoWT mice was used to assess the importance of SMO-dependent SHH 
signaling in SHH-mediated angiogenesis in ECs. The study demonstrated equal recovery in both 
eSmoNull and eSmoWT mice in terms of perfusion ratio, limb motor function, limb necrosis and 
blood vessel formation [16,26]. The results suggest the role of fibroblast-derived pro-angiogenic genes 
in indirectly activating angiogenesis that is independent of SMO proteins in EPCs and ECs. 
1.2. SHH Signal Transmission by Extracellular Vesicles 
Extracellular vesicles (EVs) are lipid bilayered structures, 30–150 nm in size, enclosing cargo 
containing messenger ribonucleic acid (mRNA), microRNAs (miRNAs), growth factors and proteins 
for transfer into recipient cells [33,34]. From biogenesis to release, all the EVs share three main stages, 
namely, i) outward budding and fission that occur at the plasma membrane, (ii) formation of early 
endosome, packaging and sorting in endoplasmic reticulum to form exosomes or EVs and (iii) release 
of exosomes or EVs into the extracellular space [33,35]. In mammals, SHH is secreted on two distinct 
types of EVs/exosomes exhibiting distinct protein and RNA composition to directly or indirectly 
activate downstream target genes [36]. Vyas et al. [36] isolated two distinct exosome fractions, P150 
and P450, from full-length SHH transfected HEK293T cells using differential ultracentrifugation 
technique. The EV pools were derived from an endocytic origin as the expression of the endocytosis 
protein RAB was found to be higher in both the fractions. 
Regulation of the SHH signaling pathway by EV-derived miRNA is divided into three levels of 
activation, namely, binding of miRNA with membrane surface receptors or proteins (PTCH1 or 
activates Rho GTPase), subsequent binding with cytoplasmic proteins GLI1, GLI 2 and GLI 3 and the 
nuclear level of activation, which is the strongest among the three levels [37–39] (Figure 2). 
Chondrocytes isolated from osteoarthritis patients showed enhanced expression of SHH, PTCH1, 
GLI 1 and metalloproteinase-13, which positively correlated with the overexpression of miRNA-602 
and miRNA-608 responsible for the activation of the above mentioned three levels [40]. EVs derived 
from cancerous cells exhibited significantly enhanced expression of SHH and GLI and positively 
correlated with the microvascular density (MVD) of tumor tissue, suggesting the important role 
played by SHH morphogens in cancer cell growth and metastasis by promoting the formation of 
microvascular network [41]. 
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Figure 2. Sonic Hedgehog (SHH) molecule or SHH secreted on extracellular vesicles (EVs) mediated 
functional improvement of endothelial progenitor cells (EPCs). In vivo, administration of exogenous 
SHH molecules increased vasculogenic EPCs. Transplantation of enhanced EPCs was beneficial for 
recovery in myocardial infarction (MI). 
According to in vitro studies, SHH secreted on EVs activated downstream signal transduction 
in EPCs by the canonical PTCH1-GLI1 signaling or through the non-canonical signaling mediated by 
pro-angiogenic miRNAs, integrin-linked kinases and ROCK dependent pathway [27,31,42,43] 
(Figure 2). In an in vivo study, SHH-coding vector transfected CD34+ cells or EPC exosomes had 
strong vasculogenic potential and aided the recovery of myocardial infarcted tissues by enhancing 
angiogenesis and reducing left ventricular fibrosis [17]. Analysis of transcriptional profile revealed 
overexpression of miRNA-126a and miRNA-296 in EPC-derived exosomes and an in vivo study 
showed improved self-renewal and vasculogenic functions in EPCs that enhanced angiogenesis in a 
murine HLI model (Table 1) [44]. Taken together, the above results indicate the importance of EVs 
derived SHH molecules or miRNAs in postnatal angiogenesis and tumor metastasis. Current 
research focuses on elucidating the functions of SHH-EVs derived miRNAs to develop novel 
therapeutic drugs for the benefit of patients suffering from cardiovascular ischemic diseases (Table 
1). 
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Table 1. Summary of pro-angiogenic and anti-senescence micro-RNAs (miRNAs) in endothelial 
progenitor cells (EPCs) and endothelial cells (ECs). 
Name of 
the 
miRNA 
Expression 
Target 
Cells 
Outcome 
Target 
Genes 
Ref. 
miR-126-
3p 
Up EPC and EC 
In vitro, presence of miR126-3p increases the length of 
tube formation. In vivo, it increases the MVD in animal 
models with HLI. 
VEGF, 
ANG-1, 
ANG-2 and 
MMP-9 
[44] 
miR-106b-
25 
Up 
EC, EPC, 
SCA-1 and 
BMMSC 
Increased tube formation capacity. Overexpression of 
individual members of the miR-106b-25 cluster 
increases viability, proliferation and  
migration of ECs.  
VEGF, SCA-
1 and FLK-1 
[45] 
miR-126 Down 
EPC, SCA-1 
and Lin- 
Silencing miR-126 in animal models with HLI 
increases mobilization of EPC, SCA-1 and Lin- cells 
from bone marrow to the site of injury and enhanced 
angiogenesis. 
SDF-1 [46] 
miR-10A 
and miR-
21 
Down EPC 
miR-10A and miR-21 regulates senescence in EPCs by 
suppressing the expression of HMGA 2.  
HMGA 2 [47] 
miR-361 Down EPC 
In vitro, KO of miR-361-5p restores VEGF levels and 
angiogenic activities in diseased EPCs. In vivo, it 
promotes blood flow and recovery of ischemic limbs in 
mice. 
VEGF [48] 
miR-34a Down EPC 
Overexpression of miR-34a significantly enhanced 
senescence and impairment in EPC that paralleled 
with 40% reduction in SIRT1. KO of SIRT1 by siRNA 
decreased angiogenesis and increased senescence in 
EPCs. 
SIRT1 and 
FOXO1 
[49] 
Abbreviations: EPC—endothelial progenitor cell; EC—endothelial cell; HLI—hind-limb ischemia; 
BMMSC—bone marrow mesenchymal stromal cells; MVD—microvascular density; Lin—lineage 
negative cells; KO—knock-out; VEGF—vascular endothelial growth factor; Ang—angiopoietin; 
MMP—matrix metalloproteinase; SCA—stem cells antigen; FLK—fetal liver kinase; SDF—stromal 
cell-derived factor; HMGA—high mobility group AT-hook; SIRT—sirtuin (silent mating type 
information regulation 2 homolog); FOX—Forkhead box. 
1.3. Impaired SHH Signaling in Cardiovascular Diseases 
Cardiovascular diseases (CVD) contribute to almost 32% of all deaths worldwide. Among them, 
ischemic diseases are a leading cause of morbidity and mortality [50,51]. EPCs in the peripheral 
bloodstream of patients with morbidities such as atherosclerosis, diabetes mellitus (DM), 
hypertension and obesity, together with risk-associated factors (smoking and western diet) are 
impaired in number, quality and function [21,52,53]. Preclinical studies related to DM, acute 
myocardial infarction (AMI), wound healing and chronic vascular inflammatory diseases indicated 
increased activation of endogenous SHH signaling pathway in non-treated group compared to that 
of the treated group, wherein exogenous administration of SHH promoted functional recovery of 
EPCs, resulting in enhanced angiogenesis, cardiomyogenesis and wound healing [26,54,55]. 
Additional studies have demonstrated the contribution of SHH molecules in the process of 
neovascularization in ischemic tissues in animal models of HLI and AMI, where the biological effects 
were brought about by an EPC enriched cell population, CD34+ cells [17,19,56] (Table 2). In a study, 
human CD34+ cells isolated from healthy volunteers or patients suffering from Burger’s disease were 
treated with SHH after administration of granulocyte colony-stimulating factor (G-CSF). The results 
indicated enhanced expression of pro-angiogenic genes in a dose-dependent manner by SHH protein, 
particularly in patient-derived CD34+ cells compared to that of CD34+ cells derived from healthy 
controls, in the presence or absence of G-CSF [17]. In vivo, streptozotocin-induced DM type 1 mice 
exhibited impaired tube-forming ability, migration and mobilization of EPCs compared to that of the 
healthy control group. EPCs of DM type 1 mice showed cross-talk between SHH and 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT pathways, which decreased the activity 
Int. J. Mol. Sci. 2018, 19, 3040 7 of 14 
 
of AKT and increased GSK-3β activity, resulting in the degradation of the SHH pathway transcription 
factor GLI1/GLI2 [57]. In human pancreatic cancer stem cells, the PI3K/AKT and SHH signaling 
pathways cooperate to inhibit the transcription factor GLI1/GLI2 to decrease cell viability and to 
induce apoptosis [58]. Compared to the control littermates, type 1 diabetic mice with myocardial 
infarction showed impaired SHH pathway with significantly decreased SHH, PTCH 1 and GLI1 
protein levels in the myocardial tissue, resulting in extended left ventricle infarct size and reduced 
capillary density leading to cardiac dysfunction [59]. GLI1 protein is essential for regulating cell-
cycle, survival, apoptosis, angiogenesis and migration of cells [24]. Patients with cardiovascular 
diseases, levels of endogenous SHH-PTCH1-GLI1 protein complex is decreased in EPCs because of 
chronic inflammation and risk factors. In such patients, administration of exogenous SHH molecules 
might aid in the recovery of PTCH1-GLI1 complex to beneficially improve the EPC functional profile 
[57,59,60]. Studies related to the transplantation of EPCs in ischemic diseases such as AMI, ischemic 
cardiomyopathy, heart failure, peripheral arterial disease (PAD) and stroke have documented lack of 
recovery of EPCs from ischemia in aged and DM patients compared to that of the control group. 
These results indicate a decrease in the concentration of PTCH1-GLI1 molecule or sensitivity of SHH 
signaling pathway receptors to EPCs to be dependent on the severity, age, type and timing of the 
disease [61–63]. Accordingly, studies related to aged mice showed decreased expression of SMO in 
the skeletal muscles [64]. 
Table 2. Endogenous and Exogenous Activation of Sonic Hedgehog (SHH) Signaling in 
Cardiovascular Diseases. 
Disease Model SHH Pathway and Cell Tx. Results Ref. 
AMI 
Activation of endogenous and 
exogenous SHH signaling by SHH–
modified human CD34+ cells and its 
exosomes 
Treatment with SHH–modified human CD34+ 
cells reduced infarct size, increased border zone 
capillary density and improved cardiac function; 
EF, FS, compared with unmodified CD34 cells or 
cells transfected with the empty vector. 
[15] 
AMI and Chronic 
MI 
Exogenous recombinant SHH 
administration and gene transfer of 
naked DNA encoding human SHH 
MI fibrosis size and apoptotic cardiomyocytes 
were reduced. MVD was increased. SHH gene 
transfer enhanced the contribution of bone 
marrow–derived endothelial progenitor cells to 
myocardial neovascularization. 
[56] 
Myocardial 
Ischemia-
Reperfusion–
Induced Injury 
Activation of endogenous HH 
signaling and administration of 
exogenous recombinant SHH 
Reduced apoptosis, fibrosis and increased 
vascularization. Exogenous SHH administration 
reduced apoptosis, increased vascularization 
and reduced  
[60] 
Post-myocardial 
ischemic-
reperfusion injury 
Activation of endogenous HH 
signaling and exogenous 
recombinant SHH administration 
Exogenous SHH administration significantly 
increased vasculogenesis-related factors 
including VEGF, FGF and ANG as well as the 
SHH signal proteins including PTCH-1, GLI 1, 
GLI 2 and SMO. 
[65] 
HLI 
SHH-treated human G-CSF 
mobilized EPCs locally injected into 
the HLI muscles 
Incubation of CD34+ cells with exogenous SHH 
molecule significantly increased vasculogenesis-
related factors including VEGFA, VEGFB, HGF 
and Pecam 1 as well as the SHH signal proteins 
including PTCH-1, GLI 1, GLI 2 and SMO at 
dose 1μg/mL. In vivo significant increase in 
angiogenesis and vasculogenesis and recovery 
by blood perfusion following HLI. 
[17] 
HLI 
SHH conditioned fibroblast media 
or exosomes 
PDGF-B, VEGF-A, HGF and IGF. PDGF-B was 
significantly upregulated and contributed to 
MVD. Improved blood flow perfusion after HLI. 
[23] 
HLI 
Combined treatment with SHH and 
EPC 
Increased incorporation of EPC within host 
vessels, reduced apoptotic of EPC and initiated 
the generation of new myocytes. 
[55] 
Diabetic wound 
healing 
Administration of exogenous 
nanoscale polymer encapsulated 
SHH 
Accelerated diabetic-induced wound closure. [44] 
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DM type 1 mouse 
was inducted AMI 
SHH + EPCs Tx 
EPC migration, tube forming ability and 
mobilization were impaired in diabetic mice 
compared to that of control. In vivo 
administration of the SHH pathway receptor 
agonist improved all the above. SHH molecules 
significantly increased capillary density and 
blood perfusion in the ischemic hind-limbs of 
diabetic mice. 
[57] 
Ischemic Stroke Administration of exogenous SHH 
SHH treatment results in enhanced functional 
recovery both in locomotor function and in 
cognitive function 1-month post-stroke. 
Increased the cerebral blood flow map by 
arterial spin labeling and immunohistochemistry 
á-smooth muscle actin and CD31 
immunostaining. 
[66] 
Abbreviation: Tx—transplantation; AMI—acute myocardial infarction; EF-ejection fraction; FS—
fractional shortening; SV—stroke volume; MVD—microvascular density; HLI—hind-limb ischemia; 
DM—diabetes mellitus; FGF—fibroblast growth factor; IGF—insulin growth factor; VEGF—vascular 
endothelial growth factor; HGF—hepatocyte growth factor; PDGF-B—platelet derived growth factor-
B; ANG—angiopoietins. 
1.4. Therapeutic Application of SHH Signaling in Cardiovascular Diseases 
In patients with end-stage ischemic disease, the effectiveness of interventional reperfusion 
therapy is hampered [67–69]. In such patients, EPC therapy is a promising therapeutic option for 
improving angiogenesis, vasculogenesis and contemporary organ preservation. Transplantation G-
CSF mobilized EPCs are safe and feasible for patients with advanced coronary artery disease or PAD, 
who are not amenable to surgical or percutaneous revascularization [70–72]. However, efficacy of 
EPC mobilization with G-CSF is very low in DM and previously EPC mobilized patients because of 
the impaired quality and quantity of EPCs [73]. In cardiovascular patients who previously underwent 
cell mobilization, SHH-mediated activation of EPC is a promising option for the functional recovery 
of EPCs [17]. Results of preclinical studies related to the therapeutic implementation of SHH proteins 
or activation of the SHH signaling pathway beneficially improved in several ischemic disease models 
such as AMI [15,43], myocardial ischemic—reperfusion, HLI [17,23,45,74], stroke [75], diabetic 
wound healing [44], skeletal myogenesis [76], osteogenesis and bone tissue formation [77] Table 2. 
The advantages and disadvantages of the therapeutic application of SHH molecules in cardiovascular 
related diseases are reviewed below. 
1.5. Ischemic Heart Diseases 
A young human heart is composed of cardiomyocytes (approximately 18%), ECs (24%) and 
mesenchymal cells or fibroblasts 58% [78]. Recent research with sophisticated cardiac single cell 
preparation and immunohistochemistry analysis revealed that the endothelial cells constitute over 
~51–54%, hematopoietic-derived cells ~3% and fibroblasts under equating to ~11% of the total cells of 
the heart when assuming ~30–33% of the cells to be cardiomyocytes [79]. As endothelial cells are the 
major cellular component of the cardiac tissue, together with SHH molecules, they could be 
therapeutically exploited to benefit patients suffering from cardiovascular diseases (Figure 2). In the 
therapeutic application of EPCs +SHH molecules, SHH signaling preserve cardiac function and 
improve cardiac recovery in the context of myocardial ischemia. To this end, combination therapy 
using intramyocardial SHH gene transfer and AMD3100-induced progenitor-cell mobilization 
significantly improved the recovery of cardiac function after the onset of MI in mouse. Mice 
administered with the combination therapy demonstrated increased MVD, reduced left ventricle 
fibrosis area and significantly enhanced expression of SDF-1α after MI [80]. One of the limitations 
associated with the broad use of SHH molecules in therapy is its short half-life in the body. In this 
regard, controlled delivery of SHH morphogens to the ischemic myocardium using a coacervate 
delivery system prolongs the therapeutic efficacy of SHH molecules. The coacervate delivery system 
protects the SHH molecules from degradation and promotes controlled release of the molecule for a 
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period of over 3 weeks [81]. Transplantation of EPCs together with controlled delivery of SHH 
morphogens to the ischemic myocardium would be a promising therapeutic tool to treat 
cardiovascular diseases. Various therapeutic applications of endogenous and exogenous activation 
of SHH signaling in AMI and myocardial ischemia-reperfusion–induced injury models are 
summarized in Table 2. 
1.6. Peripheral Arterial Diseases 
Majority of the therapeutic effects of SHH signaling were investigated using PAD model in 
mouse and rat. The importance of the therapeutic application of SHH is based on its regulatory 
function associated with the development of limbs during embryogenesis and postnatal skeletal 
myogenesis, angiogenesis, vasculogenesis and neurogenesis [6,7,40]. Endogenous SHH promotes 
infiltration of macrophages. Myocytes of mice deficient for SHH signaling showed enhanced 
expression of VEGF-A with a transient increase in angiogenesis compared to that of the healthy 
controls. These results indicate the ability of SHH molecules to limit inflammation and angiogenesis 
indirectly by signaling in myocytes, whereas exogenous administration of SHH molecules promoted 
ischemia-induced angiogenesis and skeletal myogenesis (Table 2) [19,74,76]. In a HLI model in aged 
mice, combination of SHH gene transfer and transplantation of bone marrow-derived EPCs (BM-
EPCs) could effectively promote angiogenesis and muscle regeneration compared to monotherapy 
with BM-EPCs. Treatment with SHH+ EPCs enhanced the incorporation of EPCs into the host blood 
vessels, suggesting a promising role of SHH in increasing the migration of transplanted EPCs into 
the site of ischemia to enhance angiogenesis and vasculogenesis. In vivo, combined treatment with 
SHH+ EPCs significantly reduced apoptosis in EPCs and increased proliferation of myoblast 
proliferation after the onset of HLI Table 2 [55]. These results suggest that combined treatment with 
SHH and EPC could accelerate proliferation of quiescent myogenic stem cells (satellite cells) and 
promote myotube formation by accelerating their fusion, eventually leading to the formation of 
mature myofibers supplied with new blood vessels. 
1.7. Post DM Complications 
Patients with DM are at increased risk of cardiovascular diseases and associated clinical 
complications. DM is estimated to affect 552 million people worldwide by 2030 [82]. A recent cohort 
study involving 1.9 million people with type 2 diabetes and incidence of cardiovascular diseases 
showed a strong positive association between type 2 diabetes and PADs, ischemic stroke, stable 
angina, heart failure and non-fatal MI [83]. Thus, post diabetic clinical complications are a global 
burden that requires new therapeutic strategies. Animal models with DM type 1 along with AMI or 
HLI were used for preclinical investigation of Hh signaling. Results from these experiments showed 
downstream HH signaling proteins such as PTCH1, SMO, GLI 1, GLI 2 and GLI 3 to be functionally 
impaired, indicating impairment of SHH signaling pathway in cardiovascular diseases. Combined 
treatment with exogenous recombinant SHH molecule and EPCs significantly improved the 
histological and functional parameters in experimental animals that indicated enhanced expression 
of PTCH1, SMO and GLI 1, GLI 2 and GLI 3 as detected by the transcriptome analysis [57,59]. In a 
diabetic animal model, administration of nanoscale polymer SHH conjugates accelerated wound 
closure via activation of SHH pathway. The beneficial effects of SHH treatment were evident based 
on wound revascularization detected using immunohistochemistry that quantified endothelial cells, 
CD31 and formation of neovascular structures in the wound tissues [54]. 
Following post-stroke, immediate treatment with SHH pathway agonists significantly increased 
the expression of vasculogenesis-related factors including VEGF, FGF and ANG, together with SHH 
signaling proteins PTCH1, GLI 1, GLI 2 and SMO. SHH treatment improved the neurological scores, 
reduced the infarct volume, promoted angiogenesis and neuronal survival in the ischemic boundary 
zone [75]. Strikingly, delayed treatment (post 3-8 days) with SHH pathway agonists enhanced the 
recovery of locomotor behavioral and cognitive function within 1 month of the onset of stroke, 
suggesting that a prolonged treatment window for potential treatment strategy can be modulated for 
SHH pathway post-stroke Table 2 [66]. 
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2. Conclusions 
SHH signaling pathway is a key regulator of postnatal vasculogenesis. In cardiovascular 
patients, endogenous SHH signaling pathway is impaired to varying degrees depending on the 
severity of the disease such as AMI, stroke and PAD due to the mitigated angiogenic potential of 
EPCs. Most of the preclinical experimental studies related to CVDs have shown that treatment with 
SHH molecules and EPCs could significantly enhance angiogenesis, vasculogenesis, 
cardiomyogenesis, skeletal myogenesis and neurogenesis. These therapeutic effects were evident 
even with delayed treatment. Cross-talk between SHH- and other signaling pathways, or key 
regulators such as wingless/integrated (WNT) or Notch may also be involved in maintaining the 
functional activity of EPC in angiogenesis. Thus, further research is needed to elucidate the cross-talk 
of SHH signaling with WNT, Notch, or protein kinase A (PKA). To date, most of the data available 
related to SHH signaling are derived from in vitro experiments and are difficult to be verified in vivo 
because of the presence of numerous signaling pathways and the associated cross-talk between them 
in an experimental organism. Thus, further research is required to explore the possibility of exploiting 
SHH signaling as a therapeutic tool for treating CVDs. 
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